|
 The drug, atezolizumab, was granted the status based on results of a
study, which showed the drug shrank tumors and that a majority of
patients continued to respond to the treatment after nearly a year
of follow up," Roche Chief Medical Officer Sandra Horning said.
The FDA will decide on approval by Sept. 12, the company said.
Roche is banking on atezolizumab to bring in billions in revenue by
2020 as a centre-piece of its strategy to counter the threat of
biosimilar versions of its older medicines with new drugs to fight
cancer.
(Reporting by Brenna Hughes Neghaiwi; Editing by Savio D'Souza)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
